Kamrab

/ Kamada

See prescribing information for full details.

Passive, transient post-exposure prophylaxis of rabies infection, when given immediately to individuals in cases of contact with rabid or possibly rabid animal.

Because of the life-threatening risk due to rabies, there are no contraindications to the administration of rabies immunoglobulin. However KamRAB should not be administered in repeated doses once vaccine treatment has been initiated. Repeating the dose may interfere with maximum active immunity expected from the vaccine.

Should not be administered into a blood vessel, because of the risk of shock. Injection should be made I.M. and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel.True hypersensitivity reactions are rare.Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. In case of shock, standard medicdbal treatment for shock should be implemented. Epinephrine should be available for treatment of acute anaphylactoid systems. Rarely, human rabies immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human immunoglobulin.Should be given with caution to patients with a history of prior systemic allergic reactions following administration of human immune globulin preparations. May contain residuals of IgA. Individuals with specific IgA deficiency have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products containing IgA. The attending physician who wishes to administer KamRAB to such patients must weigh the benefits of immunization against the risk of hypersensitivity reactions.As with all preparations administered I.M., bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders. Standard measures to prevent infections resulting from the use of medicdbinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicdbinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV, and for the non-enveloped viruses HAV and parvovirus B-19. There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B-19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety. It is strongly recommended that every time that KamRAB is administered to a patient, the name and batch number of the product be recorded in order to maintain a link between the patient and the batch of the product.

Most common reported side effects include headaches, dizziness, erythrocyturia and fatigue.
See prescribing information for full details.

Live attenuated virus vaccines: An interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 4 months. The injection may result in misleading positive results in serological testing. May interfere with some serological tests for red cell antibodies, for example the antiglobulin test (Coombs’ test).

No harmful effects on the course of pregnancy, or on the fetus and the neonate are to be expected, however the injection should be given to a pregnant woman only if clearly needed and when the potential benefit outweigh the potential hazards to the fetus.